depletin (CRB 15)
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
January 22, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.
(PubMed, J Immunother Cancer)
- "Obese and non-obese patients with cancer have divergent immunological responses to ICIs. Obesity is associated with reduced levels of certain inhibitory cytokines and higher expression of T-cell exhaustion markers. ICI-based therapy may more effectively reverse T-cell dysfunction in obese patients, potentially contributing to the paradoxically improved responses in this population."
Checkpoint inhibition • IO biomarker • Journal • Genetic Disorders • Obesity • Oncology • Solid Tumor • CXCL8 • IL15 • IL6
December 02, 2024
Neuropathological and cerebrospinal fluid correlates of choroid plexus inflammation in progressive multiple sclerosis.
(PubMed, Brain Pathol)
- "Analysis of 78 inflammatory molecules in paired post-mortem CSF, the levels of fibrinogen (R: 0.640, p = 8.752 x 10-6), PDGF-bb (R: 0.470, p = 0.002), CXCL13 (R: 0.428, p = 0.006) and IL15 (R: 0.327, p = 0.040) were correlated with extent of CP inflammation. Elevated fibrinogen and complement deposition were found in CP and in underlying subependymal periventricular areas, according to "surface-in" gradient associated with concomitant prominent microglia activation. CP inflammation, predominantly characterized by innate immunity, represents another key determinant of intrathecal, compartmentalised inflammation persisting in progressive MS, which may be possibly activated by fibrinogen and influence periventricular pathology, even without substantial association with clinical features."
Journal • CNS Disorders • Infectious Disease • Inflammation • Multiple Sclerosis • CD163 • CXCL13 • IL15 • ITGAX
November 03, 2023
Optimizing Ex-Vivo Expanded NK Cell- Mediated Cellular Cytotoxicity By Obinutuzumab Combined with NKTR-255 in Burkitt Lymphoma (BL)
(ASH 2023)
- "NKTR-255 is an IL-15 receptor agonist designed to activate the IL-15 pathway and NK cells and promote the survival and expansion of memory CD8+ T cells without inducing suppressive regulatory T cells (Kuo/Zalevsky, Cancer Res. We found that NKTR-255 significantly enhanced the ADCC of expanded NK cells with Obinutuzumab against rituximab-resistant BL cells in vitro with enhanced IFN- g, granzyme B and perforin release. The in vivo effects of NKTR-255 with expanded NK cells and Obinutuzumab against rituximab-resistant BL cells using humanized NSG models are very promising. Mechanisms studies of BL relapsed from the combination therapy are under investigation."
IO biomarker • Preclinical • Burkitt Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD8 • GZMA • GZMB • IFNG • IL15 • IL21
July 22, 2023
neuropathological and cerebrospinal fluid correlates of choroid plexus inflammation in progressive multiple sclerosis
(MSMilan 2023)
- "From the analysis of 78 inflammatory molecules in paired CSF, 4 of them were correlated significantly with CP inflammation: Fibrinogen (R: 0.640, p: 8.752x10-6), PDGF-bb (R: 0.470, p: 0.002), CXCL13 (R: 0.428, p: 0.006) and IL15 (R: 0.327, p: 0.040). Our results suggest a key role of CP inflammation strictly correlated with intrathecal MS inflammation, but is mainly characterized innate immune activity and fibrinogen-complement pattern reactivity."
CNS Disorders • Inflammation • Multiple Sclerosis • CD163 • CXCL13 • IL15 • ITGAX • TREM2
August 23, 2023
Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy.
(PubMed, MAbs)
- "We demonstrate that targeted on-cell prodrug conversion is more efficient than nonspecific activation in-solution. Due to the structural similarity between IL-4 and other type I cytokines relevant in cancer immunotherapy such as IL-2, IL-15, and IL-21, cytokine-PACE may be expanded to develop a variety of targeted conditionally active cytokines for cancer immunotherapy."
Journal • Oncology • IL15 • IL2 • IL21 • IL4
October 20, 2022
"📢#JEMjc Two exciting studies on engineered cytokines in immunotherapy. One by Dr. Pablo Umaña @Roche and colleagues on PD-1-cis IL-2R @Nature https://t.co/ZyAhGb2q13 One by Dr. Yang-Xin Fu @Tsinghua_Uni and colleagues on αPD-1-IL-15-R @JExpMed https://t.co/tcJX8eN5Qm"
(@Cindy_JExpMed)
IL15 • IL2RA • PD-1
January 09, 2022
Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell-Mediated Cytotoxicity Combined with Anti-CD20 or Anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL)
(TCT-ASTCT-CIBMTR 2022)
- "Polatuzumab Vedotin (PV) is an anti-CD79 mAb drug conjugate and has demonstrated significant preclinical activity against indolent CD79b+ NHL (Polson, et al, Cancer Res, 2009)...NKTR-255 is an investigational IL-15Rα-dependent, polymer-conjugated, recombinant human IL-15 agonist that retains the full spectrum of IL-15 biology, including expansion of NK cells (Miyazaki, JITC, 2021; Robinson, J Clin Invest, 2021). Objective : To investigate the anti-tumor effect of ex-vivo expanded anti-CD19 CAR NK cells combined with rituximab, Obinutuzumab, or PV with or without NKTR-255 against BL... We found that NKTR-255 + Ritux, Ob or PV significantly enhanced the in vitro cytotoxicity of anti-CD19 CAR NK cells against BL cells. The in vivo effects of NKTR-255 with anti-CD19 CAR NK cells and Ritux, Ob or PV against rituximab-sensitive and -resistant BL cells using humanized NSG models are under investigation. (This work is funded by Children’s Cancer Fund Laboratory at New York..."
Burkitt Lymphoma • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Oncology • CD79B • GZMB • IFNG
October 22, 2021
Risk assessment of latent tuberculosis infection through a multiplexed cytokine biosensor assay and machine learning feature selection.
(PubMed, Sci Rep)
- "The reduced set for increased risk included IP-10, IL-2, IFN-γ, TNF-α, IL-15, IL-17, CCL3, and CCL8 under varying normalized stimulation conditions. ROC curves determined predictive accuracies of > 80% for both LTBI diagnosis and increased risk designations. Our study findings suggest that a multiparameter diagnostic approach to detect normalized cytokine biomarker signatures might improve risk stratification in LTBI."
Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CCL3 • IFNG • IL15 • IL17A • IL2 • TNFA
March 14, 2021
[VIRTUAL] COVID-19 Prognosis in Patients with Underlying CKD and Kidney Related Complications
(ATS 2021)
- " Retrospective chart review including patients aged 18 years and older, admitted to a community hospital from March 15; 2020 to April 15; 2020, testing positive for COVID-19... Early renal involvement and underlying CKD worsen the prognosis of COVID-19 pneumonia and result in higher mortality outcomes. Such patients, especially those with findings of hematuria on admission, need closer monitoring. Furthermore, many COVID-19 patients receive steroids and anticoagulants as part of treatment regimen which will need to be further evaluated as these therapies may contribute to further damage of the kidneys."
Clinical • Acute Kidney Injury • Chronic Kidney Disease • Infectious Disease • Nephrology • Novel Coronavirus Disease • Pneumonia • Renal Disease • Respiratory Diseases
April 16, 2021
Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up.
(PubMed, JAMA Ophthalmol)
- P3 | "From January 7, 2016, to April 15, 2019 (phase 3), participants received ophthalmic examinations and visual function assessments...This information, together with a prediction model, may help clinicians and patients make informed personalized decisions about the management of ocular hypertension. ClinicalTrials.gov Identifier: NCT00000125."
Journal • Glaucoma • Ophthalmology
1 to 10
Of
10
Go to page
1